Physician profile
Aarti Ravikumar
NPI 1578844007
$3,220.97
in general payments reported to CMS, 2019-2025
8 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,969 · 2021: $95.31 · 2022: $18.54 · 2023: $16.02 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,790.00 | 2020 | |
| Abbott Laboratories | $212.56 | 2020-2021 | |
| Dexcom, INC. | $108.10 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $40.94 | 2021 | |
| Boston Scientific Corporation | $21.03 | 2021 | |
| Cequr Corporation | $18.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2023 | Tradjenta |
| Novo Nordisk INC | $13.78 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarti Ravikumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.